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Background: Quality of life (QoL) assessment has become an important aspect of the clinical management of
gastric cancer (GC), which poses a greater health threat in Chinese populations around the world. Functional
Assessment of Cancer Therapy-Gastric Module (FACT-Ga), a questionnaire developed specifically to measure QoL of
patients with GC, has never been validated in Chinese subjects. The current study was designed to examine the
psychometric properties of FACT-Ga as a GC specific QoL instrument for its future use in Chinese populations.
Methods: A sample of 67 Chinese patients with GC in the National University Hospital, Singapore was investigated
cross-sectionally. The participants independently completed either English or Chinese versions of the FACT-Ga and
the European Quality of Life-5 Dimensions (EQ-5D). Reliability was measured as the Cronbach’s α for EQ-5D, and
five subscale scores and two total scores of FACT-Ga. The sensitivity to patients’ clinical status was evaluated by
comparing EQ-5D and FACT-Ga scores between clinical subgroups classified by Clinical Stage and Treatment Intent.
The construct validity of FACT-Ga was assessed internally by examining the item-to-scale correlations and externally
by contrasting the FACT-Ga subscales with the EQ-5D domains.
Results: For both FACT-Ga and EQ-5D, patients treated with curative intent rated their QoL higher than those
treated for palliation, and early stage patients scored higher than those in the late stage. The sensitivity to clinical
status of FACT-Ga scores were differential as four of seven FACT-Ga scores were significant for Treatment Intent
while only one subscale score was significant for Clinical Stage. Six FACT-Ga scores had Cronbach’s α of 0.8 or
above indicating excellent reliability. For construct validity, 45 of 46 items converged about their respective
subscales. The monotrait-multimethod correlations between QoL constructs of FACT-Ga and EQ-5D were stronger
than the multitrait-multimethod correlations as theoretically hypothesized, suggesting good convergent and
discriminant validities.
Conclusions: Given the excellent reliability and good construct validity, FACT-Ga scores are able to distinguish
patient groups with different clinical characteristics in the expected direction. Therefore FACT-Ga can be used as a
discriminative instrument for measuring QoL of Chinese patients with GC.
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Quality of life (QoL) has been increasingly recognized as
an important outcome for cancer therapy [1]. QoL as-
sessment has special clinical significance in the manage-
ment of gastric cancer (GC) patients, as the malignancy
in a large proportion of GC patients is manifested in the
form of ascites or lymphangitis carcinomatosa, thus ren-
dering the ordinary response criteria such as tumor size
less informative. A valid and reliable instrument is crit-
ical to obtain QoL data of both clinical and public health
relevance [2].
The Functional Assessment of Chronic Illness Therapy
(FACIT) is a collection of questionnaires developed pri-
marily for the QoL measurement for various cancers.
FACIT has been established internationally as one of the
reliable and valid QoL measurement systems in clinical
oncology [3]. The core module of FACIT, the Functional
Assessment of Cancer Therapy (FACT-G), has advantage
over other cancer-generic QoL instruments in sample
size requirements [4]. Simply adding cancer specific
symptom items for a particular organ to FACT-G derives
an organ-specific cancer QoL instrument, such as those
for colon, lung and breast cancer [3]. These instruments
have been validated and widely used in different popula-
tions internationally [5-7].
However, the GC specific module based on FACT-G,
the Functional Assessment of Cancer Therapy-Gastric
(FACT-Ga) [8], has not been sufficiently validated.
There are only two recent publications validating
FACT-Ga in Western populations [9,10] and no data
for Chinese populations, who have a higher incidence
and mortality of GC [11,12] not limited to mainland
China, but also in ethnic Chinese communities in other
countries [13,14].
Previous attempts have been made to validate
FACT-G for its use in cancer patients of Chinese ethni-
city [15-17], however, GC was not covered explicitly in
these studies. Therefore, how well the FACT-G or
FACT-Ga performs in measuring the QoL of Chinese
patients with GC remains unknown. In Singapore,
Chinese constitutes 75% of the entire population and
carries an intermediate risk of GC in general and a
high risk in males aged 50 years or older [18]. Further-
more, the multilingual culture in Singapore enables the
validation of both the English and Chinese versions of
the instrument and its use in a broader population
base. As such, we designed this study to examine the
psychometric properties of FACT-Ga with a sample of
GC patients from the Singapore Chinese population.
Our aim was to validate FACT-Ga as a GC specific
QoL instrument for its use in Chinese populations.
Empirical evidence of the reliability, construct validity
and sensitivity to patients’ clinical status of FACT-Ga
was reported.Material and methods
Study sample
The study was conducted between November 2010 and
October 2011 at the National University Hospital
(NUH), Singapore. Patients from the Surgery Clinic and
the National University Cancer Institute at the NUH
were recruited using the following inclusion criteria,
1) Chinese ethnicity, 2) age 45 years or older, 3) histolo-
gically confirmed GC, 4) at least two weeks after an
operation, 5) no evidence of other concurrent severe
medical conditions, and 6) able to complete the ques-
tionnaires independently. The study was approved by
the Institutional Review Board at the NUH. All partici-
pants provided written informed consent.Quality of life instruments and data collection
Patients with GC were referred by their consulting doc-
tors to the interviewer for an assessment of their eligibil-
ity for this study. Once a patient met the inclusion
criteria, the interviewer would lead the patient to a sep-
arate room for the face-to-face session. In the presence
of the interviewer, patients independently completed two
questionnaires, the FACT-Ga (Version 4) and the 3-level
European Quality of Life-5 Dimensions (EQ-5D) in ori-
ginal English or Chinese in accordance with their lan-
guage preference. The order of the two instruments was
randomized to rule out order effects [19].
FACT-Ga evaluates the participant’s QoL over the past
seven days and consists of two parts: 1) the core module
FACT-G which comprises four general subscales, namely
physical well-being (PWB), social well-being (SWB),
emotional well-being (EWB) and functional well-being
(FWB), and 2) a 19-item gastric cancer subscale (GCS)
surveying GC symptoms and adverse effects associated
with GC treatment. The FACT-Ga items are rated on a
5-point Likert scale. Summation of item scores produces
scores for the PWB, SWB, EWB, FWB and GCS sub-
scales. The aggregate of the PWB, SWB, EWB and FWB
scores is the FACT-G total score. The FACT-Ga total
score is the sum of the FACT-G total score and GCS
subscale scores.
For the EQ-5D, participants were required to rate
their QoL on the day of interview. The EQ-5D ques-
tionnaire measures five domains of the patient’s life, i.e.
Mobility, Self-Care, Usual Activities, Pain/Discomfort
and Anxiety/Depression. The domain scores are used to
compute a utility anchored between 0 (death) and 1
(full health) [20].
For the EQ-5D utility and FACT-Ga scores, high
values indicate a better quality of life, while high EQ-
5D domain scores indicate worse health status. Clinical
information was collected directly from the patients’
case-notes.
Table 1 Demographic and clinical characteristics of the
sample
Variables Categories Value*
Age (years) 67.4 (11.9)
Survival time (years) 2.1 (2.5)
Gender Male 43 (64.2)
Female 24 (35.8)
Language Version Chinese 50 (74.6)
English 17 (25.4)
AJCC stage (6th edition) Stage 0 3 (4.5)
Stage 1 19 (28.4)
Stage 2 14 (20.9)
Stage 3 13 (19.4)
Stage 4 18 (26.9)
Metastasis No 54 (80.6)
Yes 13 (19.4)
Treatment Intent Curative 48 (71.6)
Palliative 19 (28.4)
History of surgery Total gastrectomy 12 (17.9)
Subtotal gastrectomy 37 (55.2)
Surgical procedure 4 (6.0)
No surgery 14 (20.9)
History of chemo/radiotherapy No 44 (65.7)
Yes 23 (34.3)
*Values are mean (standard deviation) for interval variables and number
(percent) for categorical variables.
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The English and Chinese questionnaires were pooled to-
gether for the analysis as the measurement equivalence
between two language versions of EQ-5D and FACT-G
has been previously confirmed in Singaporean Chinese
[16,21]. As participants were given the option not to an-
swer the seventh item of the SWB subscale, GS7 (“I am
satisfied with my sex life”), 32 (48%) participants did not
respond to this item. The SWB subscale scores for these
subjects were prorated following the FACIT Administra-
tion and Scoring Guidelines [22].
Reliability was quantified as internal consistency by
using the Cronbach’s α. An alpha value equal to or greater
than 0.70 was considered satisfactory [23]. The sensitivity
to clinical severity was tested in relation to the clinical
variables, Treatment Intent (curative vs. palliative) and
Clinical Stage (6th American Joint Committee on Cancer
(AJCC) Stage 0,1,2,3 vs. AJCC Stage 4), using the effect
size and the significance level of the Student’s t-test. Con-
struct validity of FACT-Ga was first evaluated by examin-
ing the Pearson correlation coefficient between an item
and its own scale after correction for overlap [24]. An
item-to-scale correlation reaching a minimum of 0.4 was
considered a good convergent validity for the scale.
The convergent and discriminant validities were further
evaluated using the multitrait-multimethod (MTMM) ap-
proach for incomplete design, which explored all the
inter-scale correlations among the EQ-5D domains and
FACT-Ga subscales [25]. As EQ-5D is a generic QoL in-
strument and FACT-Ga is a GC specific QoL instrument,
there is no one-to-one correspondence of the QoL con-
structs across two questionnaires. For the data interpret-
ation, we hypothesized theoretically that the FACT-Ga
PWB, EWB and FWB subscales corresponded to the
EQ-5D Pain/Discomfort, Anxiety/Depression and Usual
Activity domains respectively, whilst the FACT-Ga GCS
subscale corresponded to the EQ-5D Pain/Discomfort
domain. The correlations between these QoL construct
pairs are the monotrait-multimethod correlations in the
MTMM correlation matrix. As an incomplete design was
adopted, these correlations would not line up as a validity
diagonal. The remaining cross-instrument inter-scale cor-
relations are termed multitrait-multimethod correlations.
Both convergent validity and discriminant validity are sup-
ported if the strengths of the monotrait-multimethod cor-
relations are stronger than the multitrait-multimethod
correlations as expected a priori. The statistical software
package SPSS v17 (SPSS Inc, Chicago, Illinois) was used
to perform all analyses. A p-value less than 0.05 was con-
sidered statistically significant.
Results
Of the 80 GC patients approached, 75 agreed to partici-
pate (94% response rate). Three participants wereilliterate and five participants had severe comorbidities
or substantial missing information and so were excluded
from the study sample. Finally, a total of 67 consecutive
GC patients were recruited into the study.
The demographic and clinical characteristics of the
sample were summarized in Table 1. The mean age of
the participants was 67 years and the average survival
time was 2.13 years after diagnosis. Approximately 75%
of participants chose the Chinese version of the ques-
tionnaires. Our sample had a representative range of
clinical cases, including patients diagnosed with AJCC
stage 0 to stage 4, those with or without previous sur-
gery, metastases, and a history of chemo/radiotherapy.
The majority of these patients received treatment in hos-
pital with a curative (71.6%) rather than a palliative
intent.
The distributions of the FACT-Ga scores and EQ-5D
utility, the ceiling effect and the reliability index were
presented in Table 2. Each score had a slightly left-
skewed distribution as the medians were greater than
the means. A floor effect was not observed but a ceiling
effect was present for all scorers with notable values for
the PWB (26.87%), SWB (16.42%), EWB (16.42%) sub-
scales and the EQ-5D utility (47.76%) [26]. Cronbach’s α
Table 2 Score distributions, ceiling effect, reliability and item-scale convergence of the FACT-Ga and EQ-5D




Item correlation with its own scale
(range)
No of success† /total
(%)
PWB 24.3 (4.08) 26 5–28 26.9 0.85 0.47–0.73 7/7 (100)
SWB‡ 21.5 (5.45) 23 8–28 16.4 0.82 0.44–0.68 7/7 (100)
EWB 20.1 (3.40) 21 10–24 16.4 0.62 0.08–0.56 4/6 (67)
FWB 19.3 (6.58) 21 5–28 10.5 0.89 0.47–0.81 7/7 (100)
GCS 59.9 (12.18) 63 27–76 4.5 0.90 0.25–0.78 15/19 (79)
FACT-G 85.2 (14.55) 86 47–108 3.0 0.89 0.08–0.81 25/27 (93)
FACT-Ga 144.7 (24.51) 149 74–184 3.0 0.93 0.08–0.81 40/46 (87)
EQ-5D 0.80 (0.28) 0.88 −0.06–1 47.8 0.81 - -
*Percentage of subjects who reached the highest score of the scale.
†Success refers to an item’s Pearson correlation coefficient with its own scales equal or greater than 0.4.
‡Cronbach’s α was computed based on 6 items exclusive of GS7.
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and EQ-5D, as only the EWB subscale had a value below
0.8 [23].
In the analysis of sensitivity (Table 3), the FACT-Ga
QoL measures corresponded well with clinical severity
as indicated by Treatment Intent and Clinical Stage.
Patients treated with curative intent rated their QoL
higher than those treated for palliation. Patients diag-
nosed with an early stage of GC (AJCC stages 0, 1, 2, 3)
scored higher than patients diagnosed with the late stage
of the disease (AJCC stage 4). These observations were
in line with the direction of the overall QoL measured
by the EQ-5D utility, which was significantly different
between the subgroups of both clinical variables. How-
ever, not all FACT-Ga scores showed statistical signifi-
cance in the comparisons between clinical subgroups.
The EWB and FWB subscales, FACT-G and FACT-Ga
were significantly different between curative and pallia-
tive patients with a moderate effect size from 0.56 to
0.74 [27], while for the Clinical Stage, only the GCS sub-
scale achieved statistical significance with an effect sizeTable 3 Sensitivity of FACT-Ga scores and EQ-5D utility to clin
Treatment intent
Curative (n = 48) Palliative (n = 19) Effect size P
Mean ± SD Mean ± SD
PWB 24.8 (3.90) 23.1 (4.36) 0.45 0.112
SWB 21.3 (5.86) 21.9 (4.34) −0.10 0.686
EWB 20.6 (2.95) 18.7 (4.11) 0.65 0.036
FWB 20.6 (6.26) 16.0 (6.31) 0.74 0.008
GCS 61.4 (11.59) 56.1 (13.1) 0.46 0.106
FACT-G 87.4 (13.77) 79.6 (15.30) 0.56 0.049
FACT-Ga 148.5 (22.76) 135.2 (6.77) 0.59 0.044
EQ-5D 0.86 (0.24) 0.65 (0.33) 0.89 0.016
*Early stage: AJCC stages 0–3; Late stage: AJCC stage 4.of 0.64, and the SWB subscale achieved a borderline sig-
nificance level of p = 0.079.
The construct validity of FACT-Ga was first evaluated
by examining the item-scale convergence for each item
in Table 2. Forty (87%) of the total of 46 FACT-Ga items
had Pearson correlation coefficients of 0.4 or greater
with their own scales, indicating satisfactory convergent
validity. The remaining 6 items, GE2 and GE6 of the
EWB subscale, and items C2, HN1, C5 and E6 of the
GCS, had correlation coefficients below 0.4. However,
the correlation coefficients of 5 items (GE6, C2, HN1,
C5 and E6) had 95% confidence intervals (CI) covering
0.4 [24]. The last item GE2 (“I am satisfied with how I
am coping with my illness”) had a correlation coefficient
of 0.08 with its own subscale EWB, which was signifi-
cantly smaller (P = 0.04) than its correlation with the
FWB subscale (r = 0.43), fulfilling the definition of a def-
inite scaling error [28].
The construct validity of FACT-Ga was further evalu-
ated in the MTMM analysis using EQ-5D (Table 4). Ba-
sically, the overall QoL quantified as the EQ-5D utilityical severity
Clinical stage*
Early stage (n = 49) Late stage (n = 18) Effect size P
Mean ± SD Mean ± SD
24.7 (4.01) 23.4 (4.24) 0.32 0.264
20.9 (5.94) 23.1 (3.48) −0.36 0.079
20.4 (2.97) 19.3 (4.38) 0.36 0.256
19.9 (6.52) 17.5 (6.60) 0.37 0.180
61.8 (10.95) 54.8 (14.10) 0.64 0.035
85.9 (14.57) 83.2 (14.70) 0.18 0.511
147.4 (22.99) 137.5 (27.70) 0.43 0.146
0.84 (0.25) 0.68 (0.33) 0.66 0.031
Table 4 Multitrait-multimethod correlations matrix between EQ-5D domains and FACT-Ga subscales
EQ-5D FACT-Ga




Usual Activities 0.27* 0.37** 1
Mobility 0.31* 0.44** 0.75** 1
Self-care 0.25* 0.35** 0.66** 0.70** 1
FACT-Ga
PWB −0.66** −0.46** −0.42** −0.44** −0.29* 1
EWB −0.46** −0.57** −0.48** −0.45** −0.25* 0.64** 1
FWB −0.39** −0.52** −0.49** −0.58** −0.45** 0.48** 0.60** 1
GCS −0.63** −0.43** −0.4** −0.38** −0.33** 0.80** 0.62** 0.48** 1
SWB −0.14 −0.38* −0.20 −0.18 −0.20 0.13 0.30* 0.32** 0.13 1
Monotrait- multimethod correlations are highlighted in bold.
* P < 0.05, **p < 0.01.
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strongly correlated (r = 0.70 and r = 0.66 respectively).
The MTMM correlation matrix described in detail the
inter-scale correlation patterns within either instrument,
and more importantly across different instruments. The
latter correlations connecting the EQ-5D domains with
the FACT-Ga subscales were summarized in the lower-
left square of the MTMM matrix called Heteromethod
Block. As hypothesised a priori, the four monotrait-
multimethod correlations highlighted in Table 4 were
generally higher than the multitrait-multimethod corre-
lations. The correlation coefficients of the PWB subscale
with the Pain/Discomfort domain (r = −0.66) and the
EWB subscale with the Anxiety/Depression domain (r =
−0.57) were the highest in their respective columns and
rows. The correlation coefficient of GCS with the Pain/
Discomfort domain (r = −0.63) was comparable to that
of the PWB subscale. The correlation between the func-
tional QoL constructs, the FWB subscale in FACT-Ga
and the Usual Activity domain in EQ-5D was −0.49.
Despite being the strongest correlation in the Usual Ac-
tivity domain column, it was weaker than the two
multitrait-multimethod correlations: the Anxiety/De-
pression domain with the FWB subscale (r = −0.52) and
the Mobility domain with the FWB subscale (r = −0.58).
As the FACT-Ga SWB subscale and EQ-5D Self-care do-
main were not conceptually related to any QoL con-
struct of the other instrument, the correlations involving
these two QoL constructs were the lowest of the re-
spective rows or columns.
Discussion
Our study validated FACT-Ga in a clinically heteroge-
neous sample of Singaporean Chinese patients with GC.The study sample covered the full spectrum of clinical
cases which would allow for applying the validated ques-
tionnaire to various diagnostic groups. To the best of
our knowledge, this is the first study dedicated to valid-
ating FACT-Ga for the Chinese as the target population.
Given that the target population lives in a bilingual cul-
ture, both English and Chinese versions of the question-
naires were validated so that the FACT-Ga would be
applicable in mainland Chinese as well as overseas
Chinese populations.
For this sample of outpatients, the measurement abil-
ity of the FACT-Ga appears to be limited in evaluating
the QoL outcomes of patients who survived GC rela-
tively well. The ceiling effect was observed for all scores,
especially the PWB, SWB and EWB subscales, for which
the percentage of patients rating themselves in perfect
health exceeded a notable value of 15% (Table 2). The
core module FACT-G also showed a ceiling effect when
applied to other types of cancer patients from the same
study population [17]. A ceiling effect above 15% could
have a negative impact on other psychometric properties
of an instrument [29], for example, the sensitivity to
change, as supported by the finding that FACT-G is
weak in detecting the improvement in a patients’ health
status [9,17]. The evidence thus far seems to suggest that
the existence of a ceiling effect of FACT-Ga compro-
mises its potential as an evaluative QoL instrument.
The FACT-Ga questionnaire showed sensitivity to the
clinical characteristics of different patients groups, sup-
porting FACT-Ga as a discriminative QoL instrument.
Treatment Intent and Clinical Stage are important con-
cerns for doctors to consider when making a clinical de-
cision. The QoL profile described by the FACT-Ga scores
corresponded very well to the clinical classification by the
Zhou et al. Health and Quality of Life Outcomes 2012, 10:145 Page 6 of 8
http://www.hqlo.com/content/10/1/145two variables (Table 3). The patients in a more severe situ-
ation, i.e., those treated for palliation or those with the dis-
ease in the advanced stage rated their life worse. For
either overall or specific QoL aspects, it is clear that the
group differences are in the direction theoretically
hypothesized and consistent with the findings from the
EQ-5D.
Over and above its reflection of clinical severity of GC
malignancy, the FACT-Ga scores exhibited differential
sensitivity to clinical status. As suggested by the varying
degree of the effect size and significance level of the t-
test for each FACT-Ga score, the EWB and FWB sub-
scales were sensitive to Treatment Intent, while the GCS
and potentially the SWB subscales were sensitive to the
patient’s clinical stage. The effects of clinical classifica-
tions are moderate on the QoL outcomes (Table 3).
Furthermore, the FACT-Ga instrument revealed an
interesting finding about the social aspect of the patient’s
life, which was not measured in EQ-5D. The FACT-Ga
SWB subscale scores were higher for severe cases than
for less severe cases for both Treatment Intent and Clin-
ical Stage. This direction was opposite to that demon-
strated by other scales. It would be too simplistic to
ascribe the finding to random variation. We speculated
instead that the Chinese culture played a part in this ob-
servation considering that our study population was
Chinese. Sympathy is the essence of Chinese value sys-
tems and it could naturally be inferred that severe GC
patients would receive more love and care from the
people close to them. The SWB subscale is a measure of
a patient’s self-perception of family support and emo-
tional closeness to friends. Therefore, the reverse trend
of SWB scores is not unexpected and possibly culturally-
specific.
In our study, the FACT-Ga instrument demonstrated
excellent reliability in measuring the QoL of Chinese GC
patients. Except for the EWB subscale, Cronbach's α
values indicating internal consistency reliability were
greater than 0.80 for the instrument and other subscales
[23]. The EWB subscale had a Cronbach’s α of 0.62,
comparable to 0.60 as previously reported [9], yet below
the generally accepted standard of 0.70 [23]. As the
Cronbach’s α of a scale is computed based on the inter-
correlations among its constituent items, the extremely
low item-to-scale correlation of the EWB subscale with
its item GE2 (r = 0.08) was supposed to account for the
suboptimal reliability of the EWB subscale [28]. After
excluding item GE2, the EWB subscale had an improved
Cronbach’s α of 0.72.
The Cronbach’s α of the SWB subscale was reported
as 0.82, indicating excellent reliability of the SWB sub-
scale, based on the 67 participants who completed the
first six items of the SWB subscale. The seventh item of
the SWB subscale, GS7 asking about the sex life of thepatient, introduced a non-response rate of 48% (n = 32),
which greatly reduced the sample size for computing the
reliability index. The Cronbach’s α would drop to 0.77
based on the 35 participants with complete information
for seven SWB items. Non-response to the item GS7
was common in FACT-G validation studies in different
cancer populations [30,31]. Excluding GS7 in the calcu-
lation of Cronbach’s α for the SWB subscale has been
practiced to minimize the detriment of missing informa-
tion [30]. Doing so also prevented an unstable estimate
of the reliability index due to an insufficient sample size,
which was demonstrated by the Cronbach’s α varying
from 0.26 to 0.86 in five small samples (n = 15) validat-
ing the FACT-Ga [10].
Construct validity of FACT-Ga was explored internally
by examining the item-to-scale correlations for each
item and externally by contrasting with EQ-5D. As
hypothesized a priori, most items converged around
their individual master subscales as required for good
convergent validity. However, the Pearson correlation
coefficient of item GE2 with the EWB subscale was only
0.08 with a 95% CI below 0.4. It was also associated with
a definite scaling error implying that item GE2 should
be included in the FWB subscale rather than the EWB
subscale when FACT-Ga is used in Chinese GC patients
[28]. This finding supports the results of previous cross-
cultural studies investigating the factor structure of the
FACT-G in Asian populations [15,32].
External validation involves a MTMM correlation
matrix correlating the FACT-Ga subscales with the EQ-
5D domains. The similar QoL constructs which were
specified separately for EQ-5D and FACT-Ga yielded
stronger monotrait-multimethod correlations than the
multitrait-multimethod correlations in the Hetero-
method block (Table 4). As shown by the monotrait-
multimethod correlation coefficients, the PWB, EWB
and GCS subscales are measuring the QoL aspects as
intended. They are also able to discriminate the different
aspects of a patient’s life [25]. With regard to a patient’s
functionality, the FACT-Ga FWB subscale was not
strongly related to the Usual Activity domain of EQ-5D
as we hypothesized, but to two EQ-5D domains, the
Mobility and Anxiety/Depression domains, with similar
strengths of correlation (r = −0.58 and r = 0.52 respect-
ively). This may reflect the fact that the SWB subscale
score is an integration of the mental and physical func-
tions of a patient’s life. The QoL constructs which are
covered by only one questionnaire had the lowest cross-
instrument correlations, for example, the SWB subscale
of FACT-Ga and the Self-care domain of EQ-5D. These
results confirmed and substantiated the convergent and
discriminant validities of FACT-Ga.
However, several limitations in this study must be
noted. We were only able to recruit outpatients who
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those hospitalized for radical treatments or bedridden at
home. We acknowledge that the validity and reliability
estimates were influenced by the narrow sampling due
to logistical difficulties [33]. However, considering the
statistical property of Cronbach’s α and the correlations
indicating construct validity, a more heterogeneous
study sample generated by a wider patient pool would
strengthen the current estimates [24]. With a cross-
sectional sample, we were unable to assess test-retest re-
liability and the responsiveness of FACT-Ga measures to
QoL change over time. Finally, the sample size is suffi-
cient, yet modest, for a study validating a cancer specific
questionnaire. This may explain in part why some t-tests
comparing subscale scores were insignificant (Table 3).
A bigger cohort with follow-up information would be
necessary to consolidate the current findings.
Conclusion
Our study demonstrated that, when used in a Chinese
population, FACT-Ga is able to detect the group-
differences in QoL outcomes between the clinically dis-
tinct patient groups. The total and subscale scores from
FACT-Ga can be considered reliable and valid measures
of the QoL of Chinese patients with GC. This evidence
supports the use of FACT-Ga as a discriminative QoL
instrument alone or as a supplement to a generic QoL
instrument in clinical trials and routine clinical practice.
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